medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2013, Number 2

<< Back Next >>

An Med Asoc Med Hosp ABC 2013; 58 (2)

Morbidity and mortality in the premature neonate exposed to tocolytic therapy in the ABC Medical Center

Ortiz RME, Corres MM, García RR, José Antonio Rodríguez MJA

Language: Spanish
References: 23
Page: 106-111
PDF size: 78.07 Kb.


ABSTRACT

Background: Preterm birth is an important perinatal problem, causing great economic, social and emotional impact. Adverse effects related to tocolytic therapy are always a major concern. Objective: To describe morbidity and mortality of premature neonates who have been exposed to tocolytic therapy in The American British Cowdray Medical Center. Methods: Descriptive, retrolective and transversal study from January 2004 to December 2008. Fourty five cases of preterm birth were studied. Maternal and neonatal variables were analyzed from the patient’s records. Results: Monotherapy was used in 73.3% of the cases, orciprenaline being the most preferred utero-inhibitor (51.1%). In the group of neonates exposed to betamimetics, one presented neonatal respiratory distress syndrome, while another exposed to magnesium sulphate presented grade IV intraventricular hemorrhage. More than one complication in neonates was observed in seven neonates exposed to betamimetics, three exposed to nifedipine, two exposed to indomethacin and five exposed to multidrug therapy. Multidrug exposed neonates had a lower Apgar. Two neonatal deaths were observed, one in the group exposed to betamimetics and another in the multidrug group. Conclusions: Premature neonates exposed to multidrug therapy had a lower Apgar. The mortality rate of the preterm neonate exposed to tocolytic therapy was 0.03%.


REFERENCES

  1. Cabero RL, Fabre RE. Diagnóstico y tratamiento del parto pretérmino. En: Grupo Mexicano de Consenso. Manejo clínico de la amenaza de parto pretérmino. Ginecol Obstet Mex. 2007; 75: 29-36.

  2. Haram K, Mortensen JH, Wollen AL. Preterm delivery: an overview. Acta Obstet Gynecol Scand. 2003; 82: 687-704.

  3. Challis JR. Understanding preterm birth. Clin Invest Med. 2001; 24: 60-67.

  4. Calderón J, Vega G, Velásquez J, Morales R, Vega AJ. Factores de riesgo materno asociados al parto pretérmino. Rev Med IMSS. 2005; 43 (4): 339-342.

  5. Crowley P. Prophylactic corticosteroids for preterm Barth. In: The Cochrane Library, Issue 4. Oxford: Update Software; 2000.

  6. National Institutes of Health. 2nd consensus panel on antenatal steroids. Washington: 2000.

  7. Alan HJ, Roger FS. Choice and dose of corticosteroids for antenatal treatments. Am J Obstet Gynecol. 2004; 190 (4). 878-881.

  8. Crowley P. Prophylactic corticosteroids for preterm birth (Cochrane Review). Oxford: The Cochrane Library; 2003.

  9. Powell SL, Holt VL, Hickok DE, Easterling T, Connell FA. Recent changes in delivery site of low-birth-weight infants in Washington: impact on birth weight-specific mortality. American Journal of Obstetrics and Gynecology. 1995; 173 (5): 1585-1592.

  10. Souter D, Harding J, McCowan L, O’Donnell C, McLeay E, Baxendale H. Antenatal indomethacin-adverse fetal effects confirmed. Aust NZ J Obstet Gynaecol. 1998; 38: 11-16.

  11. Vermillion S, Newman R. Recent indomethacin tocolysis is not associated with neonatal complications in preterm infants. Am J Obstet Gynecol. 1999; 181: 1083-1086.

  12. Garder M, Owen J, Skelly S, Hauth JC. Preterm delivery after indomethacin: a risk factor for neonatal complications? J Reprod Med. 1996; 41: 903-906.

  13. Dudley D, Hardie M. Fetal and neonatal effects of indomethacin used as a tocolytic agent. Am J Obstet Gynecol. 1985; 151: 181-184.

  14. Amin SB, Sinkin RA, Glantz JC. Metaanalysis of the effect of antenatal indomethacin on neonatal outcomes. Am J Obstet Gynecol. 2007; 197: 48-486.

  15. Tsatsari V, Papatsonis D, Goffinet F, Dekker G, Carbonne B. Tocolysis with nifedipine or beta-adrenergic agonist. A meta-analysis. Obstet Gynecol. 2001; 97: 840-847.

  16. Jeyabalan A, Caritis S. Pharmacologic inhibition of preterm labor. Clin Obstet Gynecol. 2002; 45 (1); 99-113.

  17. Groome LJ, Goldenberg RL, Cliver AP, Davis RO, Copper RL. Neonatal periventricular-intraventricular hemorrhage after maternal β-sympathomimetic tocolysis. Am J Obstet Gynecol. 1992; 167: 873-879.

  18. Anotayanonth S, Subhedar NV, Garner P, Neilson JP, Harigopal S. Betamiméticos para la inhibición del trabajo de parto prematuro (Cochrane Review). In: La Biblioteca Cochrane Plus. 2008. Oxford: Update Software.

  19. Papatsonis D, Flenady V, Cole S, Liley H. Antagonistas de receptores de oxitocina para la inhibición del trabajo de parto prematuro (Cochrane Review). In: La Biblioteca Cochrane Plus, Issue 3, 2008. Oxford: Update Software.

  20. Peaceman AM, Meyer BA, Thorp JA, Parisi VM, Creasy EK. The effect of magnesium tocolysis on the fetal biophysical profile. Am J Obstet Gynecol. 1989; 161: 771-774.

  21. Mittendorf R, Covert R, Elin R, Pryde PG, Khoshnood B, Lee K. Umbilical cord serum ionized magnesium level and total pediatric mortality. Obstet Gynecol. 2001; 98 (1): 75-78.

  22. Mitterdorf R, Dambrosia J, Damman O, Pryde PG, Lee K, Ben-Ami T et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. J Pediatr. 2002; 140 (5): 540-546.

  23. Holocomb WL Jr, Shackelford GD, Petrie RH. Magnesium tocolysis and neonatal bone anormalities: a controlled study. Obstet Gynecol. 1991; 78 (4): 611-614.




2020     |     www.medigraphic.com